In a notable turn of events, Allspring Global Investments Holdings LLC has dramatically boosted its stake in Xeris Biopharma Holdings, a leading biopharmaceutical company known for its innovative therapies for patients with unmet medical needs. Documented in the latest Form 13F filing with the
In a determined effort to adhere to Nasdaq listing requirements and secure its position in a competitive market, Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, has executed a 1-for-25 reverse stock split. Effective August 19, 2024, this strategic maneuver aims to elevate the
RedHill Biopharma Ltd., known for its focus on gastrointestinal and infectious diseases, has recently achieved compliance with Nasdaq's minimum bid price requirement. This milestone ensures that the specialty biopharmaceutical company will continue to be listed on the Nasdaq Capital Market, a
In a significant move that is set to reshape the biopharmaceutical landscape, Tanvex BioPharma is acquiring Bora Biologics, a subsidiary of Bora Pharmaceuticals. This strategic merger aims to amalgamate the strengths of two industry leaders, creating a formidable force in the global Contract
Enhancing Manufacturing Capabilities Novartis is making significant strides in its efforts to expand manufacturing capabilities to meet the growing demand for radiopharmaceutical therapies aimed at treating cancer. To achieve this, the company is not only expanding an existing facility in
BioMarin Pharmaceutical, a renowned biotech firm known for its pioneering treatments for rare diseases, has recently embarked on a strategic overhaul aimed at revitalizing its growth trajectory. Faced with a period of stagnation marked by significant layoffs and halted projects, the company’s new r
